Cathie Wood's Stock Portfolio: 2025 Stock Picks
Cathie Wood is one of Wall Street's most contentious figures.
Intellia Therapeutics Inc. (NTLA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 12,536,386 | $146,174,266 | +3% | 1.21% |
| 2. | Citadel Investment Group Ken Griffin | 2,494,070 | $29,080,856 | +153% | 0% |
| 3. | Balyasny Asset Management Dmitry Balyasny | 2,306,294 | $26,891,388 | +208% | 0.04% |
| 4. | Casdin Capital Eli Casdin | 2,000,000 | $23,320,000 | 1.55% | |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,998,317 | $23,300,376 | +95% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.50 | 4,250 | Officer | 7,500 | 2019-03-06 | Filing | |
| $16.00 | 3,250 | Officer | 3,250 | 2019-03-06 | Filing | |
| $18.00 | 58,534 | Director | 2,662,180 | 2016-05-11 | Filing | |
| $18.00 | 191,466 | Director | 2,603,646 | 2016-05-11 | Filing | |
| $18.00 | 300,000 | Large Shareholder | 790,527 | 2016-05-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.97 | 265 | 19,468 | 2025-01-29 | Filing | ||
| $12.18 | 1,372 | 45,640 | 2025-01-03 | Filing | ||
| $12.18 | 7,074 | 74,497 | 2025-01-03 | Filing | ||
| $12.18 | 9,557 | 87,666 | 2025-01-03 | Filing | ||
| $12.18 | 6,502 | 59,878 | 2025-01-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,857,693 | $126,600,704 | 0% | |
| 2. | 10,190,053 | $118,816,017 | 0% | |
| 3. | 5,205,698 | $60,698,439 | 0% | |
| 4. | 3,814,546 | $44,477,612 | 0% | |
| 5. | 3,702,995 | $43,176,922 | 3.94% |
News See All
Top 11 CRISPR Stocks to Invest In
The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge technologies like pharmacogenomics, digital...
10 Best Gene Therapy Stocks to Buy Right Now
Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.
10 Worst ARK Stocks To Buy According to Short Sellers
Cathie Wood of ARK Investment is one of Wall Street's most well-known hedge fund bosses.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2024 Earnings Call Transcript
Operator: Good morning and welcome to Intellia Therapeutics’ Third Quarter 2024 Financial Results Conference Call. My name is Drew and I will be your conference operator today.
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds
The pharmaceutical industry remains a hub of patent innovation, driven by evolving treatment paradigms, unmet medical needs, and the rising influence of technologies like pharmacogenomics, digital therapeutics...
10 Most Promising Biotech Stocks According to Hedge Funds
Biotechnology stocks are known for their high risk, making them some of the most volatile in the market.
10 Stocks That Will Change the World
If we were to try and summarize one of the biggest ways how to make money on the stock market, it'd include buying stocks of firms that have changed the world.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2024 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2024 Earnings Call Transcript August 8, 2024Intellia Therapeutics, Inc. misses on earnings expectations.
Is Intellia Therapeutics, Inc. (NASDAQ:NTLA) the Most Promising Gene Therapy Stock to Buy Now?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Intellia Therapeutics, Inc.
Billionaire Hedge Funds
